Eosinophilic fasciitis (EF) is a rare disease characterized by inflammation of the connective tissue that affects the fascia that envelops muscles. The characteristic feature of this disease is the presence of eosinophils, a type of white blood cell, in the affected tissue. Eosinophilic fasciitis is preceded by swelling, thickening of the skin, and limited mobility, which can lead to significant functional impairment and a deterioration in the quality of life of patients. The disease most often occurs in young and middle-aged people, and its nature remains not fully understood, which complicates diagnosis and the choice of treatment methods.
History of the disease and interesting historical facts
Eosinophilic fasciitis was first described in 1974, when a group of researchers led by Dr. Patrick Gaes presented the results of observations of 10 patients with this disease. Since then, many studies have been conducted aimed at a deeper understanding of the mechanism of its development and clinical manifestations. An interesting fact is that EF was initially considered a manifestation of systemic scleroderma, but further studies showed that these conditions are separate diseases. Despite its long history, many aspects of EF are still a subject of discussion in the medical community.
Epidemiology
Based on clinical observations, eosinophilic fasciitis occurs with a frequency of about 1-2 cases per 1 million population per year. Targeted studies show that the disease affects men more (approximately 60% cases), while women account for 40%. Although EF can occur at any age, it most often occurs in people between the ages of 20 and 50. Since the disease is rare, more research is needed to accurately determine its prevalence in different regions of the world.
Genetic predisposition to this disease
At present, there is no complete information about the genetic predisposition to eosinophilic fasciitis. Some studies have identified genes involved in the regulation of the immune response, such as the HLA-DR genes associated with inflammatory diseases. Mutations in these genes may increase the risk of developing EF. However, further studies focusing on genomic associations and the mechanism of disease formation are needed to draw final conclusions.
Risk factors for the development of this disease
There are several factors that can contribute to the development of eosinophilic fasciitis:
- Physical factors: injuries, excessive physical activity, often leading to microtrauma of tissues.
- Chemical factors: Exposure to certain toxic substances such as bromine, silicates and other chemical agents may increase the risk.
- Other factors: infections, vaccinations and the presence of other autoimmune diseases may also play a role in the pathogenesis of EF.
Diagnosis of this disease
Diagnosis of eosinophilic fasciitis includes several stages:
- The main symptoms are swelling, pain, thickening of the skin and limited joint mobility.
- Laboratory tests: complete blood count with emphasis on eosinophil levels and the presence of inflammatory markers.
- Radiological examinations: MRI and ultrasound can show changes in the structure of the fascia.
- Other diagnostic methods: skin or fascia biopsy provides the opportunity for histological analysis.
- Differential diagnosis: Other conditions such as systemic sclerosis and dermatomyositis must be excluded.
Treatment
Treatment for eosinophilic fasciitis can be varied and depends on the stage of the disease:
- General treatment: it is important to limit physical activity and rest.
- Pharmacological treatment: Corticosteroids such as prednisolone are used to reduce inflammation.
- Surgery: In rare cases, surgery may be needed to remove affected tissue.
- Other treatments: Physical therapy and the use of nonsteroidal anti-inflammatory drugs (NSAIDs) may also help relieve symptoms.
List of medications used to treat this disease
Common medications used to treat eosinophilic fasciitis include:
- Prednisolone.
- Methotrexate.
- Azafen.
- Hydroxychloroquine.
Disease monitoring
Monitoring the condition of a patient with eosinophilic fasciitis includes regular follow-up examinations:
- Control stages: every 1-3 months to assess the clinical condition and response to therapy.
- Prognosis: With timely treatment, most patients show significant improvement.
- Complications: Potential complications may include limited mobility and psycho-emotional disorders.
Age-related features of the disease
Eosinophilic fasciitis can present differently depending on the patient's age group:
- Young people (20 to 30 years old) most often seek treatment with acute symptoms and severe inflammation.
- Middle-aged people (30 to 50 years) may demonstrate chronicity of the process and more complex clinical variants.
- Older patients (over 50 years of age) may experience milder forms of the disease, but with a high risk of complications.
Questions and Answers
- What are the main symptoms of eosinophilic fasciitis? The main symptoms are swelling, thickening of the skin, pain and limited joint mobility.
- How is this disease diagnosed? Diagnosis is based on clinical symptoms, laboratory tests and biopsy.
- How to treat eosinophilic fasciitis? Treatment includes corticosteroids, NSAIDs, and, in some cases, surgery.
- What is the prognosis for patients with eosinophilic fasciitis? With timely diagnosis and treatment, the prognosis is favorable, with most patients showing improvement.
- How can age affect the course of the disease? Young people are more likely to experience acute symptoms, while older people may experience complications and chronicity of the process.
Dr. Oleg Korzhikov recommends paying close attention to your health and promptly contacting specialists when symptoms such as swelling and pain in the limbs occur. He also emphasizes the importance of conducting all necessary examinations and prescribing adequate treatment to avoid possible complications and maintain a high quality of life.
